Previous close | 2.5400 |
Open | N/A |
Bid | 2.0000 |
Ask | 2.6000 |
Strike | 23.00 |
Expiry date | 2024-11-15 |
Day's range | 2.5400 - 2.5400 |
Contract range | N/A |
Volume | |
Open interest | 50 |
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revenue Falls Short, EPS Beats Estimates Despite Restructuring Costs
ALAMEDA, Calif., April 30, 2024--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.